



Judith Greciet, invited as guest speaker at international Allicense Conference

May 5-6, 2015 – San Francisco, CA

Paris (France), Copenhagen (Denmark), March 31, 2015 [6:30 pm CET] – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Judith Greciet, CEO of Onxeo, has been invited to participate to the 2015 Allicense Conference as a panelist for the session entitled “Eat or Be Eaten—The Specialty Pharma Survival Story”.

As one of the active deal-making organizations during the last months, especially with the last year’s acquisition and merger of TopoTarget by BioAlliance Pharma, Onxeo is a particularly compelling story, and certainly unique among mid-size European-based biotechs. Judith Greciet will contribute as a player and a witness to this very timely topic, with the recent Onxeo’s story of increasing size and critical mass through a merger in order to emerge as new global player in the orphan oncology drugs area.

Allicense Conference brings together professionals from the Pharma, Biotech and Financial communities. It offers opportunities for exchange of information and debate, especially in dealmaking, licensing and business development areas.

The conference takes place on May 5 and 6 (the session “Eat or Be Eaten—The Specialty Pharma Survival Story” is on the 6th at 2:15pm) at the Park Central Hotel in San Francisco.

About Allicense

The Allicense Conference is the leading event for dealmaking, licensing and business development professionals, and is hosted by Thomson Reuters, the leading provider of intelligence for the life sciences Business Development and Licensing market.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to “make the difference”. The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or

achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62